New combo therapy aims to control prostate cancer without castration
NCT ID NCT06084338
First seen Jan 06, 2026
Summary
This phase 2 trial is testing whether a combination of targeted radiation (SBRT) and a radioactive drug called Pluvicto can control metastatic castration-resistant prostate cancer without the need for ongoing hormone therapy. Sixty participants will stop castration and receive the treatments, with half also getting testosterone gel. The main goal is to see if the cancer stays under control for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Edward Hines Jr. VA Hospital, Hines, IL
RECRUITINGHines, Illinois, 60141-3030, United States
Contact Email: •••••@•••••
-
Richard L. Roudebush VA Medical Center, Indianapolis, IN
RECRUITINGIndianapolis, Indiana, 46202-2884, United States
Contact Email: •••••@•••••
-
VA Ann Arbor Healthcare System, Ann Arbor, MI
RECRUITINGAnn Arbor, Michigan, 48105-2303, United States
Contact Email: •••••@•••••
-
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
RECRUITINGWest Los Angeles, California, 90073-1003, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pluvicto (Lu177-PSMA) and stereotactic ablative radiotherapy
What this could lead to
If successful, this could offer a way to control metastatic prostate cancer without long-term hormone therapy, potentially improving quality of life.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply broadly. The combination therapy also carries risks like radiation side effects and toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.